FOLH1 and prostate cancer: Looking forward, we hope that the introduction of new tracers, such as the 18F-PSMA-1007, as well as the combination of PSMA PET/CT with MRI, may further contribute to future precision in staging localized prostate cancer [29,30,31,32], possibly overcoming the aforementioned caveat in applying PSMA PET/CT-guided imaging.